



## Carmignac P. Grande Europe: Letter from the Fund Manager



Author(s)  
Mark Denham

Published  
May 9, 2022

Length  
5 r

Carmignac Portfolio Grande Europe A EUR Acc lost -12.6% in the first quarter of 2022, versus -6.0% of its reference indicator<sup>1</sup>, mainly on the back of the sectorial rotation characterizing the market in the period.

-12.6  
%  
Performance of the Fund  
over the quarter for the A EUR Share class.

-6.0  
%  
Performance of the  
reference indicator<sup>1</sup> over the quarter.

Past performance is not necessarily indicative of future performance. The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. Performances are net of fees (excluding possible entrance fees charged by the distributor). Source: Carmignac, Bloomberg, 31/03/2022. Performance of the A EUR Acc share class (ISIN code: LU0099161993). <sup>1</sup>Reference Indicator: Stoxx 600 (Reinvested net dividends).

## European Equity Market Review

The first quarter of the year was an eventful one. In the period, the dominant factor affecting European equities was the response of monetary authorities in US and Europe to rising inflation. This activity led to interest rate increases, tapering planning, and withdrawal of quantitative easing measures introduced during the Covid crisis. Although economies worldwide are emerging from Covid lockdowns, many bottlenecks affecting supply chains, logistics, and the labour market are still characterising the environment. This backdrop, which is compounded by high energy prices exacerbated by the Russian invasion of Ukraine, precipitated a sharp market rotation into so-called "value" sectors such as Oils and Commodities. In the first few months of the year, these segments were among the few areas of the market delivering a positive return; however, given they do not meet our financial criteria which is based on high levels of profit and reinvestment, we have virtually no exposure to them. Conversely, higher quality companies and sectors such as Technology, Industrials, and Consumer Goods - where we are focused, and which have relatively higher multiples - came under the most pressure from the rising interest rates environment. This rotation experienced in the market accounts for all the performance disparity in the quarter between the Fund and its reference indicator. To note, we had no direct exposure to Russia or Ukraine and, even if many holdings have some sales in those countries, the overall Fund's indirect exposure there is proportionally small.

## Portfolio Management

At the end of last year, we anticipated the risk of a painful rotation due to inflationary pressure by reducing exposure in the portfolio to what we thought were the most vulnerable areas such as: recently listed companies through IPOs, loss making companies among innovative sectors like biotech and food delivery, as well as the highest multiple stocks. While we cannot control the rotation, we can make sure that the targeted 35-40 companies we own in the Fund are maintaining their profit trajectory. Consequently, as during the full year reporting season all but one of our names met or beat our expectations, we only divested from the one exception, namely Delivery Hero - a food delivery company - where profitability was once again deferred by management. Nevertheless, for the most part, our companies were able to offset rising cost pressure and deliver good results, so we took any weakness as an opportunity to add to some of the names such as: Adyen (electronics payments), Assa Abloy (locks), and LVMH (luxury goods).

Among the sector led movements, there were some highlights. Our pharmaceutical names were relatively strong. Novo Nordisk - a portfolio long-term holding - saw demand for their GLP-1 treatments, for both diabetes and new indication obesity, accelerating and consequently set encouraging growth ambition for 2022. Roche - which instead was added in the period - is another player in the Health Care industry which enhances the Fund's somehow more defensive bias, a stance called by the current environment. Visibility of revenues and diversified growth drivers leveraging newly launched drugs are in fact important attributes to our investment thesis around the name. Another highlight in the quarter were our renewable energy stocks Vestas (wind turbines) and Orsted (wind farm development), both of which outperformed the market. High and rising energy price levels worldwide were initially caused by supply chain disruption and subsequently exacerbated by the Russian invasion of Ukraine. As a result, economics of renewable energy are becoming relatively more attractive. Additionally, Europe's concerns around energy supply and its accessibility have accelerated discussions for energy independence. This has pushed both the European Union at an aggregate level and local governments to plan the increase of sovereign energy supply. In this context, renewable energy forms are critical and will become even more attractive for investors. In particular, even if current results for both Orsted and Vestas are being adversely impacted by input cost pressure, we believe market participants will review their medium and long-term outlooks, thus we continue to reinforce this area of the Fund, on any price weakness.

The market rotation we have seen in the period, an extreme downward stock prices movement among high quality / highly valued names, have also created opportunities for us. This generalised downward volatility allowed us to add new names that we believed were previously too expensive, despite being attractive fundamentally. An example is Swiss listed dental equipment company Straumann, market leader in dental implants. While continuing to grow through innovation within the implant division, the company is also building a growing market share in the promising clear aligners segment. Cleared aligners are more fashionable and discrete options used as an alternative to wires, for straightening teeth. We started a position in the name after a more than 30% drop in the stock share price. Another opportunity was Genmab, a Danish biotech company with several products already on the market.

## Outlook & Strategy Reminder

With few additions/deletions to the Fund in the period, we head into the remaining part of 2022 with the broad structure of the portfolio unchanged but representing an attractive entry point for investors, having fallen 30% from its recent peak in November 2021. The Fund remains a consequence of our bottom-up stock picking process which focuses on SRI and quality companies, defined by their profitability and high return on capital.

Carmignac Portfolio Grande Europe

# A high conviction, sustainable European equity strategy

[Discover the fund page](#)

## Carmignac Portfolio Grande Europe A EUR Acc

ISIN: LU0099161993

Recommended  
minimum  
investment horizon



### Main risks of the Fund

**EQUITY:** The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization.

**CURRENCY:** Currency risk is linked to exposure to a currency other than the Fund's valuation currency, either through direct investment or the use of forward financial instruments.

**DISCRETIONARY MANAGEMENT:** Anticipations of financial market changes made by the Management Company have a direct effect on the Fund's performance, which depends on the stocks selected.

The Fund presents a risk of loss of capital.

**Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.**

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA. The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds' prospectus, KIDs, NAVs and annual reports are available at [www.carmignac.com](http://www.carmignac.com), or upon request to the Management Company. Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

**In France, Luxembourg, Sweden:** The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. The Funds' prospectus, KIDs, NAV and annual reports are available at [www.carmignac.com](http://www.carmignac.com), or upon request to the Management Company.

**In the United Kingdom:** the Funds' respective prospectuses, KIIDs and annual reports are available at [www.carmignac.co.uk](http://www.carmignac.co.uk), or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the "Company") is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the "ACD") of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.

**In Switzerland:** the prospectus, KIDs and annual report are available at [www.carmignac.ch](http://www.carmignac.ch), or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights in English on the following links: [UK](#) ; [Switzerland](#) ; [France](#) ; [Luxembourg](#) ; [Sweden](#).